Compare TG Therapeutics Inc (TGTX) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $236.11 (market cap $44.37B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 5.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals.
| TGTX | TTWO | |
|---|---|---|
Market Cap | $8.26B | $44.37B |
Sector | Health | Media |
52-Week High | $59.06 | $262.29 |
52-Week Low | $26.39 | $189.69 |
Enterprise Value | $8.50B | $45.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Take-Two Interactive (TTWO) trades at $235.93, down 0.31% on the day, with a neutral technical signal despite recent earnings beats. The company shows strong revenue growth to $5.63 billion in 2025 but faces profitability challenges with a net income margin of -4.48%. Analyst sentiment remains overwhelmingly positive with a 78.95% buy rating and a consensus price target of $302.50, driven by anticipation for Grand Theft Auto VI.
The outlook hinges on GTA VI execution, with potential for significant upside if launch succeeds, but risks include persistent negative cash flow from operations and high debt levels. Investors should weigh strong analyst confidence against fundamental weaknesses in profitability and cash generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
